About Natera

About Natera

Natera is a rapidly-growing diagnostics company with proprietary bioinformatics and molecular technology for analyzing DNA. Natera’s complex technology has been proven clinically and commercially in the prenatal testing space and the Company is actively researching its applications in the liquid biopsy space for developing products with oncology applications.

Since 2009, Natera has launched seven molecular diagnostic tests, many of which are available through major health plans accounting for more than 140 million covered lives in the United States. The Company’s own robust laboratory processes thousands of genetic tests per month.

Natera’s goal is to transform the way people – both providers and patients – respond to and manage genetic diseases.

Learn More About Natera

Stock Information

NTRA (Common Stock)
ExchangeNASDAQ CM (US Dollar)
Price$18.54
Change (%) Stock is Down 0.77 (3.99%)
Volume3,383,085
Data as of 04/18/19 4:00 p.m. ET
Minimum 15 minute delay
Refresh quote
Stock chart for: NTRA.O.  Currently trading at $18.54 with a 52 week high of $29.62 and a 52 week low of $10.77.

Recent News

Natera Announces Pricing of Follow-On Offering - 04/17/19
SAN CARLOS, Calif., April 17, 2019 /PRNewswire/ -- Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA testing, today announced the pricing of its underwritten public offering of 5,263,158 shares of its common stock at a price to the public... More»
Natera Launches Proposed Follow-On Offering - 04/16/19
SAN CARLOS, Calif., April 16, 2019 /PRNewswire/ -- Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA testing, today announced the launch of a proposed follow-on public offering of $100,000,000 of shares of its common stock. In addition, N... More»
New Publication Validates Clinical Performance of Signatera for Recurrence Monitoring and MRD Assessment in Breast Cancer - 04/16/19
Molecular Residual Disease Detected Up to Two Years Prior to Clinical Relapse, with Zero False Positives SAN CARLOS, Calif., April 16, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), Cancer Research UK, Imperial College London and t... More»
Natera Announces Plans to Commercialize Tumor Whole Exome Sequencing from Plasma - 04/10/19
Represents Next Advancement in Company's Innovative Oncology ctDNA Program SAN CARLOS, Calif., April 10, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA) Natera, a leader in cell-free DNA testing, today announced plans to commercialize a researc... More»
Medicare Issues Draft Local Coverage Determination for Natera's New Prospera™ Kidney Transplant Rejection Test - 03/28/19
Represents Major Reimbursement Milestone on Company's Path to Commercialization in 2019 SAN CARLOS, Calif., March 28, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that Palmet... More»

Upcoming Events

Shareholder Tools